A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema

Exclusion Criteria

• •1. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (also known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
• •2. Use of therapies prescribed for the prevention of HAE attacks prior to Screening:
• •1. lanadelumab within 90 days
• •2. berotralstat within 21 days
• •3. all other prophylactic therapies, within 7 days
• •3. Any exposure to angiotensin-converting enzyme inhibitors or any estrogen containing medications with systemic absorption (such as hormonal contraceptives or hormone replacement therapy) within 28 days prior to Screening.
• •4. Any exposure to androgens (for example, stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within 7 days prior to Screening.